Athersys Inc. (Nasdaq: ATHX) reported disappointing results from a Phase 2
study of its MultiStem cell therapy to treat ischemic stroke patients sending the stock price tumbling 87 cents to $1.31.
Disappointing study results for Athersys
April 17, 2015 at 12:37 PM EDT